Literature DB >> 2129511

Reprogramming the immune system for tolerance with monoclonal antibodies.

S P Cobbold1, S X Qin, H Waldmann.   

Abstract

Monoclonal antibodies to CD4, CD8 and CD11a can be used in vivo either to deplete or functionally block T cells to create a tolerance permissive environment. Short courses of non-depleting CD4 and CD8 antibodies were used to induce tolerance separately in CD4+ and CD8+ T cells either to foreign immunoglobulins, bone marrow, or skin grafts. Tolerance was obtained to minor (non-MHC) transplantation antigens without T cell depletion even in actively sensitized mice, or to MHC plus minor antigens presented directly by skin grafts using combinations of depleting followed by blockading CD4 and CD8 antibodies. In all cases, tolerance was specific to the antigen/tissue given under cover of antibody treatment, and in one example it could be shown that T cells directed to MLS-1a had been forced into an anergic state. This induction of tolerant, anergic T cells in the periphery is able to explain many of the features associated with tolerance, not only in the model systems using foreign antigens, but also in the normal regulation of anti-self responses and its failure in autoimmune diseases. It is our new found ability to use antigen under the cover of antibody treatment to accurately control the pattern of tolerant T cells in vivo that we refer to by using the term 'reprogramming'. We also describe the clinical treatment of one patient with an autoimmune vasculitis based on the ideas developed from the mouse models.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2129511

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  10 in total

Review 1.  Immuno-intervention for the induction of transplantation tolerance through mixed chimerism.

Authors:  David H Sachs; Megan Sykes; Tatsuo Kawai; A Benedict Cosimi
Journal:  Semin Immunol       Date:  2011-08-11       Impact factor: 11.130

Review 2.  Induction of tolerance through mixed chimerism.

Authors:  David H Sachs; Tatsuo Kawai; Megan Sykes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-01-01       Impact factor: 6.915

3.  Expression of B7.1 in a MUC1-expressing mouse mammary epithelial tumour cell line inhibits tumorigenicity but does not induce autoimmunity in MUC1 transgenic mice.

Authors:  M Smith; J M Burchell; R Graham; E P Cohen; J Taylor-Papadimitriou
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

Review 4.  Mixed hematopoietic chimerism and transplantation tolerance.

Authors:  B Nikolic; M Sykes
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 5.  Hematopoietic cell transplantation for tolerance induction: animal models to clinical trials.

Authors:  Megan Sykes
Journal:  Transplantation       Date:  2009-02-15       Impact factor: 4.939

Review 6.  Autoantigens in thyroid diseases.

Authors:  K Dawe; P Hutchings; B Champion; A Cooke; I Roitt
Journal:  Springer Semin Immunopathol       Date:  1993

Review 7.  Immune tolerance in recipients of combined haploidentical bone marrow and kidney transplantation.

Authors:  M Sykes
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 8.  Where is biological therapy going?

Authors:  H Schulze-Koops; J R Kalden
Journal:  Arthritis Res       Date:  2000-06-29

Review 9.  Botanical immunodrugs: scope and opportunities.

Authors:  Bhushan Patwardhan; Manish Gautam
Journal:  Drug Discov Today       Date:  2005-04-01       Impact factor: 7.851

10.  Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.

Authors:  Leslie P Cousens; Federico Mingozzi; Sander van der Marel; Yan Su; Richard Garman; Valerie Ferreira; William Martin; David W Scott; Anne S De Groot
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.